camostat: Clinical Trials

5 trials of camostat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 unknown. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Terminated 2, Unknown 1
Phase 21Completed 1

Follow camostat: new trials by email Literature Review of camostat trials Research Report on camostat

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
Camostat, Placebo, Molnupiravir - Covid19, SARS-CoV Infection
Phase 3TerminatedKU Leuven442021-06-152022-10-03
CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
Camostat Mesylate, Placebo - Covid19
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris702020-12-032022-02-10
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
FOY-305, Placebo - SARS-CoV-2 Infection (COVID-19)
Phase 3CompletedOno Pharmaceutical Co., Ltd.1552020-11-092024-04-05
ACTIV-2: A Study for Outpatients With COVID-19
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19
Phase 2 / Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)40442020-08-192024-08-02
Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus
hydroxychloroquine in combination with camostat mesylate, Hydroxychloroquine in combination of Azithromycin - COVID - 19
Phase 3UnknownSheba Medical Center2502020-04-112020-04-21

Conditions studied

COVID-19 (5)  ·  Severe Acute Respiratory Syndrome (2)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)  ·  Nidovirales Infections (1)  ·  RNA Virus Infections (1)  ·  Virus Diseases (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (1)  ·  KU Leuven (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Ono Pharmaceutical Co., Ltd. (1)  ·  Sheba Medical Center (1)

Countries

Argentina (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  France (1)  ·  Guatemala (1)  ·  Israel (1)  ·  Japan (1)  ·  Mexico (1)  ·  Philippines (1)  ·  Puerto Rico (1)  ·  South Africa (1)  ·  United States (1)

Top investigators

David Smith, MD, MAS (1)  ·  Naoyuki Komura (1)

Results publications

PMID 34473343, PMID 34981077, PMID 35713300, PMID 35793677, PMID 35797235, PMID 35995785, PMID 36163020, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 39018444, PMID 39028902, PMID 41823222, PMID 42148571